BPC-157

Scientific identity: BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a partial sequence of BPC — body protection compound — a protein isolated from human gastric juice. BPC-157 is a stable synthetic fragment; the parent protein BPC itself is not directly available as a research tool. BPC-157 does not contain disulfide bridges and has a linear, unmodified structure. It is notable for its reported stability in gastric acid in experimental systems — a property attributed to its proline-rich N-terminal sequence — which has made it a relevant research tool in gastrointestinal biology models.

Peptide class: Synthetic pentadecapeptide; gastric juice protein-derived fragment; body protection compound partial sequence analogue.

Primary research contexts: Nitric oxide (NO) signaling and eNOS pathway research; growth factor receptor biology including VEGFR2 and EGFR; tendon fibroblast and ligament cell biology; gastrointestinal mucosal tissue models; angiogenesis research in experimental systems.

Research areas: Nitric oxide signalling research, growth factor receptor pharmacology, tendon and ligament biology, gastrointestinal tissue research, angiogenesis models, musculoskeletal cell biology, wound biology research in experimental systems.

Available quantities: 5mg and 10mg per vial.

Purity: Greater than 99%, confirmed by HPLC and LC-MS analysis at the batch level.

Analytical documentation: A batch-specific Certificate of Analysis is available on the Longevia Research website, covering compound identity, purity, and lot traceability.

Research-use classification: For laboratory research use only. Not for human or veterinary use, clinical diagnostics, or any in-vivo application in humans.

Nitric Oxide Signaling Research

A frequently investigated proposed mechanism in the BPC-157 preclinical literature involves the nitric oxide (NO) pathway — specifically endothelial nitric oxide synthase (eNOS) activation and downstream NO production. Cell-based and animal studies have examined whether BPC-157 influences eNOS expression, NO synthesis, and related vascular signaling parameters in defined experimental systems. NO is a well-characterised signaling molecule with roles in vascular biology, tissue remodeling, and cellular homeostasis. The proposed relationship between BPC-157 and the NO pathway has been characterised primarily in rodent models and cell culture systems; the molecular mechanism of interaction with eNOS or upstream signaling components remains an active area of investigation.

Growth Factor Receptor Research

Published research has examined BPC-157 in relation to growth factor receptor signaling — including vascular endothelial growth factor receptor 2 (VEGFR2) and epidermal growth factor receptor (EGFR) — in cell-based and animal experimental systems. Studies have investigated receptor expression, phosphorylation, and downstream signaling pathway activity following BPC-157 exposure in defined cell models. These findings represent experimental observations in specific cell systems and should not be interpreted as establishing receptor binding or direct agonist/antagonist activity for BPC-157 without reference to the specific experimental conditions reported in each study.

Tendon, Ligament, and Musculoskeletal Research

BPC-157 has been examined in a substantial body of animal model research involving tendon, ligament, and musculoskeletal tissue biology. Rodent studies have used experimental tendon transection, crush injury, and ligament damage models to investigate tissue parameters including fibroblast activity, collagen deposition, and histological endpoints following BPC-157 administration. These animal findings are among the most cited in the BPC-157 preclinical literature and are model-specific observations that cannot be directly extrapolated to human tissue outcomes.

Gastrointestinal Research

BPC-157's origin as a gastric juice protein-derived fragment has motivated research in gastrointestinal tissue models. Animal studies have examined BPC-157 in experimental models of gastrointestinal mucosal injury, including chemical and physical insult models in rodents. The peptide's reported stability in gastric acid conditions — attributed to its proline-rich sequence — makes it of specific interest in gastrointestinal research contexts where peptide stability under acidic conditions is experimentally relevant.

Research Status

BPC-157 is a research-stage compound. As of the time of publication, no completed human clinical trial of BPC-157 appears in peer-reviewed literature or public clinical trial registries. All controlled findings in the published literature derive from cell-based and animal experimental systems. It holds no regulatory approval for any indication in any jurisdiction.

Reliable research begins with accurately characterised material. For a linear pentadecapeptide such as BPC-157, that means confirming the full 15-residue sequence and purity at the batch level — because the proline-rich N-terminal region of BPC-157 presents specific synthesis challenges, and truncated or deletion sequences can co-elute with the full-length peptide under some chromatographic conditions, making rigorous LC-MS identity confirmation particularly important for this compound.

Purity assessment: Each production lot is characterised to greater than 99% purity by high-performance liquid chromatography (HPLC). Chromatographic purity data is reported on the batch Certificate of Analysis.

Identity confirmation: Peptide identity and full 15-residue sequence integrity are confirmed by mass spectrometry (LC-MS), providing molecular-weight verification consistent with the complete linear pentadecapeptide. HPLC and LC-MS data together confirm that the material supplied corresponds to the labelled compound at the labelled purity.

Batch traceability and Certificate of Analysis: Every vial of BPC-157 5mg and 10mg is traceable to a specific production lot. A batch-specific Certificate of Analysis is accessible directly on the Longevia Research website, covering purity, identity, and lot information. Researchers evaluating this material for assay work are encouraged to review the current batch documentation before use, since analytical specifications are applied at the lot level.

Handling: This material should be handled by qualified personnel using appropriate laboratory technique and personal protective equipment, consistent with institutional protocols for research-grade synthetic peptides.

Longevia Research supplies BPC-157 5mg and 10mg for laboratory and in-vitro research use only. The product is intended for use by qualified researchers and trained laboratory personnel in appropriate controlled research environments.

BPC-157 is a synthetic research peptide supplied strictly as a research tool. It is not a drug, not a dietary supplement, not a food or food ingredient, and not a cosmetic. No regulatory authority has approved BPC-157 for any human or veterinary therapeutic use, and Longevia does not supply it for administration to humans or animals, for clinical diagnostics, or for any therapeutic purpose.

Longevia provides no dosing instructions, administration guidance, treatment protocols, or reconstitution recommendations for this compound. The scientific literature summarised on this product page describes experimental observations exclusively in defined cell-based and animal model systems. Those findings are not medical claims and should not be interpreted as evidence of human efficacy, human safety, or fitness for any clinical application.

The purchaser assumes full responsibility for lawful acquisition, handling, storage, use, and disposal of this material, and for compliance with all applicable local, state, federal, and institutional regulations. By purchasing this product, the buyer confirms that it will be used solely for legitimate laboratory research purposes by qualified personnel, and that its acquisition and intended use comply with applicable laws in the buyer's jurisdiction.